読み込み中
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
前日終値
$4.90
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
日中レンジ
現在 $4.90
52週レンジ
現在 $4.90
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
37
割高
センチメント
51
まちまち
リスク
47
やや高いリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
日中レンジ
現在 $4.90
52週レンジ
現在 $4.90
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上原価 | 64.7万 USD | 66.8万 USD | — | — |
| 粗利益 | −64.7万 USD | −66.8万 USD | — | — |
| 研究開発 | 6026.3万 USD | 5728.8万 USD | 4062.6万 USD | 3460.5万 USD |
| 販売・一般管理 | 2871.9万 USD | 1326.8万 USD | 970.7万 USD | 676.7万 USD |
| 営業費用 | 8833.5万 USD | 6988.8万 USD | 5033.3万 USD | 4137.2万 USD |
| 受取利息 | 1329.5万 USD | 817万 USD | 276.9万 USD | 113.2万 USD |
| 減価償却費と償却費 | 64.7万 USD | 66.8万 USD | 58.3万 USD | 12.2万 USD |
| 営業利益 | −8898.2万 USD | −7055.6万 USD | −5033.3万 USD | −4137.2万 USD |
| 純利益 | −7526.8万 USD | −6168.8万 USD | −4726.3万 USD | −4024万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI563.59万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM242.36万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard U.S. Momentum Factor ETFVFMO242.2万0.12%19億 USD0.13%$230.11+1.02%
Vanguard Extended Market ETFVXF100.9万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB100.89万0.01%108.2億 USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO84.53万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO63.8万0.00%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA49.93万0.00%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard U.S. Momentum Factor ETFVFMOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
